title: [Role amiodarone in sinus rhythm maintenance after successful cardioversion in patients with chronic non-valvular atrial fibrillation].
abstract: Antiarrhythmic drugs prophylaxis may improve late outcome of electrical cardioversion (CV) in persistent atrial fibrillation (AF). We conducted a prospective study of the efficacy of sequential antiarrhythmic drug therapy in sinus rhythm (SR) maintenance after a successful elective CV in patients (pts) with persistent nonvalvular AF. Investigated group and methods. 104 pts (60.4 +/- 7.9 years old) with persistent AF underwent CV. Following SR restoration pts received one of these antiarrhythmic drugs (Drug I): propafenone, sotalol, disopyramide. In case of arrhythmia recurrence we performed a second CV and pts received another drug from the mentioned before (Drug II). If treatment proved to be unsuccessful pts received amiodarone (Drug III) and a third CV was attempted. Following an unsuccessful first CV pts received loading dose amiodarone and another CV was attempted. In case of SR restoration amiodarone was administered continuously.
  
  
  RESULTS
  First CV was successful in 53.8% pts. Following 1 year 27 pts (48.2%) presented with SR treated with Drug I (median not exist); Drug II proved to be effective in 2 pts (7.0%) (median 14 days). Amiodarone as the third antiarrhythmic agent (Drug III), administered in pts who had previously AF recurrence during the first two antiarrhythmic agents, occurred effective in additional 13 pts (median 307 days) who remained free from AF for one year from the initiation of sequential antiarrhythmic therapy. 48 pts in whom the first CV was ineffective, received amiodarone. During the loading period SR was restored in 10 pts (20.8%). The remaining 38 pts underwent repeated CV and SR was restored in 24 (62.3%) of them. Long-term amiodarone treatment maintained SR during the follow-up period in 24 (70.6%) pts. In total, amiodarone helped to maintain SR in 56.0% of pts.
  
  
  CONCLUSIONS
  Sequential antiarrhythmic drug therapy improve arrhythmia prognosis in AF within a 12 months observation period. Amiodarone seems to be the most effective antiarrhythmic drug also in pts who required a second CV proceeded by amiodarone treatment to restore SR.
authors.affiliation: Katedra i Klinika Chorób Wewnetrznych i Kardiologii I Wydziału Lekarskiego AM w Warszawie. dkosior@amwaw.edu.pl
authors.forename: Dariusz
authors.initials: D
authors.lastname: Kosior
authors.forename: Marcin
authors.initials: M
authors.lastname: Szulc
authors.forename: Maria
authors.initials: M
authors.lastname: Zawadzka
authors.forename: Magdalena
authors.initials: M
authors.lastname: Pierścińska
authors.forename: Sławomir
authors.initials: S
authors.lastname: Stawicki
authors.forename: Daniel
authors.initials: D
authors.lastname: Rabczenko
authors.forename: Adam
authors.initials: A
authors.lastname: Torbicki
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Opolski
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000494:pharmacology* / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001146:Arrhythmia, Sinus / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D004554:Electric Countershock / Q000295:instrumentation*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012849:Sinoatrial Node / Q000187:drug effects*
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone